

Index

Note: Page numbers followed by “*f*” indicate figures, “*t*” indicate tables, and “*s*” indicate schemes.

A

- Abnormal amyloid beta (A β) plaque
 - generation, 286
- Acetylated glycosyl phosphates,
 - pyrophosphate synthesis using, 44–46, 45*s*
- Acetylated glycosyl phosphorimidazolidates,
 - pyrophosphate synthesis using, 46–47, 47*s*
- Acetylcholinesterase (AChE), 158–159, 163
- Acetyl-CoA carboxylase (ACC), 69–70, 75–76
- Acidic oligosaccharide sugar chain (AOSC), 167–168
- Acquired immunodeficiency syndrome (AIDS), 226
- Activated prenol derivatives, polyprenyl
 - diphosphate synthesis from, 42, 42*s*
- Active pharmaceutical ingredient (API), 65–66
- Adenosine diphosphate (ADP), 60
- Adenosine monophosphate (AMP), 60–61
- Adenosine triphosphate (ATP), 60
- Aerobic cobalt-catalyzed tetrahydrofuran
 - synthesis
 - DFT calculation for, 6, 8*s*
 - mechanistic investigation, 5–6, 7*s*
- Aerobic Mukaiyama oxidative cyclization, 3–12
- AIF. *See* All-ion fragmentation (AIF)
- Alcohol consumption, 124
- Alkaloids, 101–102*t*, 346–347
- Alkenol, 13–14
- All-ion fragmentation (AIF), 339–340
- α -lipoic acid (α LA), 74–77
 - AMPK activation, 75–76, 76*f*
 - antioxidant properties, 74
 - in mitochondrial bioenergetic reactions, 74
 - molecular structure, 74*s*
 - obesity preventative properties, 75–76
 - in treatment of diabetes, 74
- Alzheimer’s disease (AD), 158–159, 286
 - natural products for, 159–170
 - Panax ginseng*, 166–170
 - pathology and targets for, 158–159, 159*f*
 - Withania somnifera*, 160–166
- Ambrosia. *See* Bee bread
- Amino acids, 101–102*t*, 345–346
- 4-Aminobenzamide, 65–66
- Ammonium dolichyl phosphates, 37
- Ammonium polyprenyl diphosphates, 34
- AMP-activated protein kinase (AMPK), 59–63
 - activation, 60, 62–63, 62*f*
 - as target for drug development, 63–65
 - α subunit, 60
 - β subunit, 60
 - deactivation, 60–61
 - dephosphorylation, 60–61
 - in energy metabolism, 62–63, 62*f*
 - γ subunit, 60
 - in glucose homeostasis, 59–60
 - mechanisms, 60
 - metformin hydrochloride, 58–59, 63
 - myristoylation, 62
 - natural products as potential activators, 65–81
 - phosphorylation of, 60
 - regulation by adenosine monophosphate (AMP), 60–61, 61*f*
 - TDZs, 64
- Amphidinolide F, total synthesis of, 25–26, 25*s*
- Amphidinolides C, fragments synthesis of, 23–26, 24–25*s*, 24*f*
- AMPK activators, in treatment of diabetes mellitus, 65–81
- Amyloid hypothesis, 158–159
- Amyloid plaques, 158–159
- Amyloid precursor protein (APP), 158–159
- Amyotrophy, 120–121
- Anaferine, 165–166, 165*f*
- Andrographolides, 251–252
- Anion-exchange chromatography, 37
- Annonaceous acetogenins (AGEs), 13–18
- Anolignan, 247–248
- Anthocyanidins, 199
- Anthocyanins, 199

- P¹-[11-(Anthracen-9-ylmethoxy)undecyl]-P²-
 (2-acetamido-2-deoxy- α -
 D-galactopyranosyl) diphosphate
 (AntUn-PP-GalNAc), 46
 11-[(9-Anthracenyl)methoxy]undecyl
 phosphate, 37
 Anthrocyamin, 101–102*r*
 Anti-Alzheimer's activity, 286
 Antibiotics, 92
 Anticancer activity
 amphidinolide C, 23–24
 amphidinolide F, 23–24
 and anti-tumor, 288–289
 bullatacin, 16–17
 goniotrionin, 17
 mucocin, 15
 Anti-depressant activity, 287–288
 Antidiabetic activity, 287
 Antidiabetic drug
 mechanism of action, 128–129, 129*f*, 130*r*
 selection criteria, 128, 128*f*
 Anti-HIV drugs, in combination with
 medicinal plants, 254
 Antihypertensive activities, 285
 Anti-inflammatory activity, 286
 Anti-nociceptive activity, 286
 Antioxidant activity, 286–287
 Anti-Parkinson's activity, 287
 Antiretroviral therapy (ART), 226
 Anti-tumor activity, 288–289
 Apalbumin, 187
 Aphrodisiac activity, 285–286
 Apigenin, 199
 Apigenin-7-*O*-beta-D-glucopyranoside,
 247–248
 Apisimin, 187
 Apitherapy, 175–176
 Apitoxin, 189
 (–)-Aplysiallene, total synthesis of, 20–21, 22*s*
 Apocarotenoids biosynthesis, 282–283
 Apricot kernels, 310
 ArgusLab molecular docking software, 257
 Aromin, total synthesis of, 18, 19*s*
 Artificial intelligence (AI), 107, 108*r*
 Artificial sweeteners, 124
 “Ashwagandha”, 160
 (+)-Asimilobin, total synthesis of, 14–15, 15*s*
 (–)-Asimilobin, total synthesis of, 14–15, 15*s*
 Asperga. *See* Bee bread
 Assistant therapy, 105
 Asymmetric unit
 α LA-nicotinamide cocrystal, 74, 75*f*
 of BBR-acesulfame cocrystals, 71–72, 72*f*
 of BBR-saccharin cocrystals, 71–72, 72*f*
 of cocrystal RSV-piperazine, 67, 68*f*
 of cocrystal RSV-piperine, 67, 67*f*
 Aurantiamide acetate, 257
 Autodock 4 software, 257
 Autonomic neuropathy, 120–121
 Ayurveda, 130–149
 Ayurveda, Homeopathy, Naturopathy, Siddha,
 Unani, and Yoga (AYUSH), 126
- ## B
- BAs. *See* Berberine alkaloids (BAs)
 Bee bread, 184–185, 185*f*
 Bee glue. *See* Propolis
 Bee pollens, 183–184
 Bee venom, 189–191, 191*f*
 for allergic disorders, 190
 compositions, 190
 electro-shock methods, 189–190
 enzymes, 190
 melittin, 190
 peptides, 190
 pharmacological component of, 190
 powder, 191*f*
 proteins, 190
 surgical collection, 189–190
 Berberine (BBR), 71–73
 AMPK activation by, 72–73
 bioavailability, 73
 chloride salt, 71
 in diabetes treatment, 73
 molecular structure, 71*s*
 therapeutic benefits, 72
 Berberine alkaloids (BAs), 346–347
 Bergenin, 249
 β -amyloid, 158–159
 β -amyloid peptide (BAP), 160–161
 β -diketone-cobalt(II) complexes, 3–5
 β -diketone ligands, 3–5
 β -secretase, 158–159
 β -sitosterol, 165–166, 165*f*
 Betulinic acid, hydrogenation of, 256–257
 Bevirimat, 250
 Biguanides, 125
 Bioactive natural products (BNPs), 332–333
 Biologically active molecules, 2–3, 2*s*
 Bis-(benzyloxy)-(diisopropylamino)-phosphine
 (BBDIP), phosphorylation with, 39–40,
 39*f*
 Bis-(2-cyanoethyl)-*N,N*-
 diisopropylphosphoramidite (BCDIP),
 phosphorylation with, 38, 38*f*

Bis-(9H-fluoren-9-ylmethyl)-
diisopropylamidophosphite (BFDIP),
phosphorylation with, 38–39,
38–39*f*
Bis-tetrahydrofuran, synthesis of
oxidation-alkyne addition-oxidation
Mukaiyama reaction in, 11–12, 13*s*
Blood pressure reduction, 285
Blossom honey, 177
BNPs. *See* Bioactive natural products (BNPs)
(+)-Bovidic acid, total synthesis of,
19–20, 20*s*
Box–Behnken design (BBD) technique,
283–284
Brain-derived neurotrophic factor (BDNF),
162
Brain, effect of hyperglycemia in, 123
Bran, 322–323
Bromophycolide A, 263
 β -sheet generation, 286
Bullatacin, total synthesis of, 16–17, 17*s*
Butyrylcholinesterase (BuChE), 158–159

C

Cages, 182
Calanolides, 247–248
Calcium spirulan, 263
cAMP response element binding (CREB),
287–288
Cancer treatment, by herbal medicines,
103–105
Capillary electrophoretic (CE) analysis,
flavonoids, 216–217
1,1'-Carbonyldiimidazole (CDI), 43–44
Cardioprotective activities, 285
Cardiovascular system, hyperglycemia and,
121–122
Carotenoids, 274–275, 345
Cataract, 120
Catechin, 199–200, 249
Catecholamine, 122
Cauliflower, glucosinolates in, 347–348
Cellulose adsorbents, 210–211
Centroradialis/terminal flower 1 (CEN/TFL1),
291
Chagosensine, total synthesis of, 20, 21*s*
Chemical drugs
developments, 100
herbal medicine *vs.*, 95–97
Chinese water chestnut peels (CWCPs), 206
Chiral tetrahydrofuran (THF), 2–3, 2*s*
Chlorogenic acid, 256–257
Chromatographic techniques, flavonoids,
210–215
Chromatography, 333–334
based separation modes, 334–335
gas, 338–341
high-performance liquid chromatography
(HPLC), 335–338
nano-liquid chromatography (Nano-LC),
337–338
orbitrap-MS, 340–341
TOF-MS, 341
ultra-high-performance liquid
chromatography (UHPLC), 336
Chronic constipation, 309
Cisapride, 310
cis-fused 2,6-dioxabicyclo[3,3,0]octane
skeleton, 20–21
(*S*)-citronellal, 20
Citronellyl phosphate (Cit-P), 37
CMI-977 (LDP 977), total synthesis of, 21–22,
22*s*
Cobalt (II) complexes, 3–5
Co(modp)₂ catalyst, 5
Co(nmp)₂ catalyst, 7, 9
Cocrystal RSV-piperazine, asymmetric unit of,
67, 68*f*
Cocrystal RSV-piperine, asymmetric unit of,
67, 67*f*
Cocrystals, 66–67
Column anion-exchange chromatography, 44
Combinatorial therapy, 254
Compound K (CK), 78, 78*s*
Constipation, 307
classification, 307
definition of, 305–307
lifestyle and dietary modification, 309
normal-transit, 307–308
pregnancy, 308–309
prevalence rate of, 305–306
slow transit, 308
treatment of, 306–307, 309, 312–319*t*
(*see also* Pharmacological treatments,
of constipation)
Conventional solvent extraction (CSE), 209
Corn bran, 322–323
Corolyceps, 97
Coronary artery diseases (CAD), 122
Corydalis yanhusuo, 346–347
Co(tfa)₂(H₂O)(O₂) system, 3, 4*f*
CREB. *See* cAMP response element binding
(CREB)
Crocins, 251–252, 284–287
anti-apoptotic effect, 288–289

Crocus sativus L. (saffron)
 biological activity, 274–275, 276–280*t*
 cultivation, 274
 ethanolic extracts, 288–289
 habit and botanical description, 275–280
 pharmacology (*see* Pharmacology, saffron)
 phytochemistry (*see* Phytochemistry, saffron)
 production enhancement (*see* Production enhancement, saffron)
 wild species, 281
Cruciferous, glucosinolates in, 347–348
 Cultured plant extracts, antioxidant capacity of, 363
 Curcumin, 249
 2-Cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (CDIPCP), 42–43
 Cyclic voltammetry (CV), 217–218
 Cyclocapitelline, total synthesis of, 18–19, 19*s*
 Cyclohexadienyl-type radicals, 365
 Cystathionine- β -synthase (CBS), 60

D

Dark honeys, 177
 Defecation disorders, 308
 5,6-Dehydrokawain (DK), 249
 12-Deoxyphorbol-13-phenylacetate, 251
 Dephosphorylation, AMP-activated protein kinase (AMPK), 60–61
 Derivative spectrophotometry (DS), 216
 Diabetes mellitus (DM), 118
 AMPK activators in treatment of, 65–81
 associated complications, 120–124
 berberine (BBR) in, 73
 classification of, 118, 119*t*
 dietary treatment, 124
 epidemiology, 118–120
 ginseng in, 77
 global burden of, 118–120
 herbal medicine for, 125–129
 incidence, 57–58, 118
 Indian traditional system and medicine for management of, 130–149
 insulin therapy insulin dependent diabetes mellitus, 125
 management of, 124–125
 metformin for, 127–128
 non-insulin dependent, drug treatment for, 125
 physical activity, 124–125
 plants used for, 129, 131–147*t*
 resveratrol (RSV) in, 70–71
 risk factors, 57–58

type 1, 58
 type 2, 58–59
 Diabetic nephropathy, 120
 Diabetic neuropathy, 120–121
 Diabetic retinopathy (DR), 120
 3,5-Dicaffeoylquinic acid, 249
 Dienediol, 14–15
 (*S,S*)-diepoxybutane, 20–21
 Dietary treatment, diabetes mellitus (DM), 124
 Digitoxin, 92
 7,8-Dihydrocalanolid B, 256–257
 2,3-Dihdropolyprenol, 42–43
 2,3-Dihdropolyprenols, 31, 32*f*
 2,3-Dihdropolyprenyl (dolichyl) phosphates, preparation of, 36
 2,3-Dihdroprenyl diphosphate *N,N'*-diacetylchitobiose, 45–46
 Diisopropylammonium PhOUn-P, 46
 Diisopropylethylamine (DIEA), 42–43
 Dimethoxycoumarin, 251
 Disaccharide derivatives, 46
 Dock pose analysis, 257
 Double bond substitution, in Mukaiyama oxidative cyclization, 9–10, 11*s*
 Drug developments, 93
 AMP-activated protein kinase (AMPK)
 activation as target for, 63–65
 chemical, 100
 chemical structures, 101
 Chinese versions of, 110*f*
 natural, Western version of, 109*f*
 Dynamic ultrasonic extraction (DUE) method, 216

E

Electrochemical analysis, flavonoids, 217–218
 Electroencephalography (EEG), 169
 Electron paramagnetic resonance (EPR), 355–358
 advantages, 359–361
 applications, 358
 free radicals assessment, in irradiated plants, 365
 liposomal characteristics, 366
 natural products, evaluating antioxidant activity of, 358–364
 paramagnetic impurities detection, in natural products, 366–367
 vegetable oil oxidative stability, evaluation of, 364–365
 Electrophilic double bonds, in Mukaiyama oxidative cyclization, 10–11, 12*s*

Ellagic acid, 257
 Emetine, 247–248
 Endothelial cell dysfunction, 122
 Endothelin, 122
 Enzyme-assisted ultrasonicmicrowave
 synergistic extraction (EAUMSE), 206
 Epoxy-alkene, 25–26
 EPR. *See* Electron paramagnetic resonance
 (EPR)
 Essential oils, 262–263
 Ethanol, 283–284
 Ether bonds, 2–3
 1-Ethyl-3-methylimidazolium bromide,
 209–210
 Eukaryotic dolichol (Dol-OH), 33
 Exercise, 124–125

F

Factorial-based response surface modeling
 (RSM) ultrasonic extraction, 283–284
 Fagaronine, 247–248
 Farnesol, 38
 Fatty acid synthase (FAS), 69–70
 Fig, 320–321
 Flavan oligomers, 199
 Flavanols, 199–200
 Flavones, 200
 Flavonoids, 101–102*t*, 129, 183–184, 198
 advanced extraction techniques, 201–210
 analytical techniques, 211–212, 213–214*t*
 anti-cancer activity of, 200
 capillary electrophoretic (CE) analysis,
 216–217
 chromatographic techniques, 212–215
 conventional extraction process, 202
 electrochemical analysis, 217–218
 extraction methods, advantages and
 disadvantages of, 205*t*
 identification and quantification techniques,
 211–218
 ionic liquid extraction (ILE), 209–210
 microwave-assisted extraction (MAE),
 202–206
 non-conventional extraction methods,
 203–204*t*
 nuclear structure, 198, 199*f*
 pressurized solvent extraction (PSE),
 207–208
 sample cleanup techniques, 210–211
 sample preparation, 200–201
 sources, in plants and human health,
 199–200, 201*f*

 spectrophotometric analysis, 215–216
 subgroups, 198, 199*f*
 supercritical fluid extraction (SFE), 208–209
 ultrasound-assisted extraction (UAE),
 206–207
 Flavonols, 199
 Flaxseed, 321
 Flow injection analysis (FIA), 217
 Fluorescent labeled P¹-, P²-(α -
 D-galactopyranosyl) diphosphate, 44
 Free carbon radical, 8–9
 Free radicals assessment, in irradiated plants,
 365
 Frontal Assessment Battery (FAB), 169
 Fruits, antioxidant capacity of, 363
 Functional foods, 127
 Fuzi, herb, 97

G

GABA_A receptors, 164–165
 Gallotannin, 249
 γ -secretase, 158–159
 Garciosaterpene A, 247–248
 Gas chromatography (GC), 210–212, 338–339
 high resolution mass spectrometry (HRMS),
 339–341
G. biloba, 159
 Gel permeation chromatography (GPC), 211
 Genetic diversity assessment, in saffron,
 293–294
 Gentamicin, 286–287
 Geraniol, 18–19, 38
 Gestational diabetes, 118
 Gigantetrocin A, total synthesis of, 13–14, 14*s*
 Ginseng, 77–79, 97
 active components, 77
 AMPK activation, 77–78
 bioavailability, 79
 in diabetes treatment, 77
 protopanaxadiol (PD), 77, 77*s*
 protopanaxatriol (PT), 77, 77*s*
 Ginsenoside Rb1, 78–79, 78*s*
 Ginsenoside Rg2, 79
 Ginsenosides, 77, 168–169, 168*f*
 Gintonin, 167
 Glibenclamide, 125
 Glucosinolates, 347–348
 Glutathione peroxidase (GSH-Px), 167–168
 Glycemic index (GI), of honey, 178–179
 Glycoprotein, 228–229
 Glycosyltransferases (GTs), 32, 47–48
Goldenberry calyx, 342

(-)-Goniotrionin, total synthesis of, 17, 18s
 Granulocyte, 121
 Greener reagent, 8–9
 Guttiferone A, 251–252

H

Heating reflux extraction (HRE), 206

Herbal medicines

- artificial intelligence, 107
- cancer treatment by, 103–105
- Chinese systems, 93–94, 104*t*
- in clinic, 95
- current situations, 97
- for diabetes mellitus (DM), 125–129
- disease treatments, 94
- economic consideration, 96
- financial ease, 93
- herbs, costs of, 97
- heritage and present convention, 100
- history, 97–100
- limitation of, 96
- literature sorting, 103
- medical knowledge promotions, 106
- modern diagnosis application, 107
- vs. natural chemical drugs, 95
- neoplasm metastasis treatment by, 107–108
- patho-therapeutic relation, 102
- therapeutic adjustments in, 108
- therapeutics against emerging diseases, 106–107
- tradition pass-down, 103
- vs. western therapy convention in China, 106*t*

Herbs, antioxidant capacity of, 363

1,6-Hexanediol, 19–20

5-Hexenols, 9

High hydrostatic pressure extraction (HHPE), 207–208

Highly active antiretroviral therapy (HAART), 226

High performance liquid chromatography (HPLC), 210–212, 213–214*t*, 335–338

High performance liquid chromatography (HPLC) grade methanol, 283–284

High performance thin layer chromatography (HPTLC), 284

High resolution mass spectrometry (HRMS), 331–332

Hinokiflavone, 247–248

HIV. *See* Human immunodeficiency virus (HIV)

HIV integrase (IN), 248–249

HIV protease (PR), 249–250

HIV reverse transcriptase (RT), 229–248

Honey, 176–179, 176*f*

- adulteration of, 178

- antibacterial properties of, 178

- antimicrobial activity of, 177

- composition of, 176–177

- enzymes, 178

- glycemic index (GI), 178–179

- healing effect of, 178

- purity of, 176

- sugars in, 177

- total phenolic content (TPC) of, 178

- types of, 177

Honey bee, 175–176

Honey bee products, and apitherapeutic properties

- bee bread, 184–185, 185*f*

- bee venom, 189–191, 191*f*

- honey, 176–179, 176*f*

- pollen, 182–184, 183*f*

- propolis, 179–182, 180*f*

- royal jelly (RJ), 186–189, 186*f*, 187–188*t*, 188*f*

Honey Codex, 178

Honeydew, 177

HPLC. *See* High performance liquid chromatography (HPLC)

HPLC-DAD-MS/MS method, 215

HPTLC. *See* High performance thin layer chromatography (HPTLC)

HRMS. *See* High resolution mass spectrometry (HRMS)

HT4 receptor agonists, 310

Human immunodeficiency virus (HIV), 226–227

- advanced drug delivery techniques, 264

- anti-HIV drugs in combination with

- medicinal plants, 254

- chemically synthesized anti-HIV

- phytochemical derivatives, 256–257

- essential oils, 262–263

- in silico* anti-HIV studies, 257–258

- integrase, 248–249

- in vitro* screening of medicinal plants, 263–264

- life cycle, 227–229, 230*f*

- marine herbal resource, 263

- plant products in management of infection, 254–256

- plants with assorted activity profile, 258–262, 259–261*t*

- plants with broad-spectrum activity against, 254

- plants with inhibitory activity against HIV targets, 231–241*t*, 250–252
 - protease, 249–250
 - reverse transcriptase, 229–248
 - structure and genome organization, 228, 228*f*
 - symptoms, 226
 - Hydro-alcoholic extract, of stigma, 287–288
 - Hydrogenation, of betulinic acid, 256–257
 - Hydrogenolysis, 39
 - 4-Hydroperoxy-2-decenoic acid ethyl ester (HPO-DAEE), 188*f*
 - Hyperfine interaction, 357–358
 - Hyperglycemia
 - and cardiovascular system, 121–122
 - effects in brain, 123
 - and immune function, 121
 - and inflammation, 123
 - and microvascular complications, 120–121
 - and oxidative stress, 123–124
 - and thrombosis, 122
- I**
- IBS. *See* Irritable Bowel Syndrome (IBS)
 - iGEMDOCK software, 257
 - Immune function, hyperglycemia and, 121
 - Indian Ginseng. *See* *Withania somnifera*
 - Indian traditional system of medicine
 - for management of diabetes mellitus (DM), 130–149
 - Infection, 121
 - Inflammation, hyperglycemia and, 123
 - In silico* anti-HIV studies, 257–258
 - Insulin, 58
 - Insulin resistance (IR), 59
 - Insulin therapy insulin dependent diabetes mellitus (IDDM), 125
 - Integrase (IN), 248
 - Interleukin (IL-6), 123
 - International Diabetes Foundation (IDF), 119–120
 - Inter-retro transposon amplified polymorphism (IRAP), 293–294
 - Intracerebroventricular streptozotocin (ICV-STZ), 161–162
 - Intrinsic dissolution rate (IDR), 65–66
 - In vitro* propagation, 292–293
 - Ionic liquid extraction (ILE), flavonoids, 209–210
 - Ionic liquids (ILs), 209
 - IRAP. *See* Inter-retro transposon amplified polymorphism (IRAP)
 - Irradiation method, 365
 - Irritable Bowel Syndrome (IBS), 307
 - Ischemia reperfusion (IR), 286–287
 - Ischemic penumbra, 123
 - Isoflavones, 199
 - Isoniazid, 65–66
 - Isoxazoles, synthesis of, 9, 10*s*
- J**
- Justiprocumin B, 252–253
- K**
- Kaempferol, 199
 - Kampo/herbal medicine, 311
 - Kiwifruit, 321–322
 - Korean Mini-Mental State Examination (K-MMSE), 169
 - Korean Red Ginseng (KRG), on cognitive function, 169
- L**
- Latent autoimmune diabetes in adults (LADA), 118
 - Laxative foods, 311–324
 - bran, 322–323
 - fig, 320–321
 - flaxseed, 321
 - kiwifruit, 321–322
 - plum, 320
 - probiotic and prebiotic foods, 323–324
 - LC-MS. *See* Liquid chromatography-mass spectroscopy (LC-MS)
 - Lettuce, antioxidant capacity of, 362
 - Leukemia, 288–289
 - Limit of detection (LOD), 212–215
 - Limit of quantification (LOQ), 212–215
 - Limonin, 251–252
 - Linaclotide, 310–311
 - Linoleic acid, 169–170, 170*f*
 - Lipid-linked oligosaccharides (LLO), 33, 49
 - Lipophilic compounds, antioxidant capacity of, 364
 - Lipoprotein receptor-related protein (LRP), 161
 - Liposomal characteristics, 366
 - Lippia origanoides* (*Verbenaceae*), 342–345
 - Liquid chromatography (LC), 331–332
 - Liquid chromatography-high resolution mass spectrometry (LC-HRMS), 332
 - alkaloids, 346–347
 - amino acid, 345–346
 - applications, 342–345, 343–344*t*
 - carotenoids, 345

Liquid chromatography-high resolution mass spectrometry (LC-HRMS) (*Continued*)
 data-dependent, 339–340, 340f
 glucosinolates, 347–348
 with Orbitrap-MS and TOF-MS, 339–340, 341f
 peptides, 345–346
 polyphenols, 342–345
 terpenes/terpenoids, 347
 Liquid chromatography-mass spectroscopy (LC-MS), 284
Lobelia chinensis, 342
 Lubiprostone, 310–311
 Lunasin, 345–346
 Luteolin, 199

M

Macrovascular disorders, 121
 Major RJ proteins (MRJPs), 187, 188t
 Mallotojaponin, 247–248
 Malondialdehyde (MDA), 163–164
 Mangiferin, 250
 Mangosteen, antioxidant capacity of, 364
 Manuka honey, 178
 Maslinic acid, 250
 Mass spectrometry (MS), 331–332
 Maturity onset diabetes of youth (MODY), 118
 Medicinal chemistry, 92–93
 Medicinal plants
 anti- HIV drugs in combination with, 254
 in vitro screening of, 263–264
 Medium-chain fatty acids (MCFAs), 187–188
 MEKC. *See* Micellar electrokinetic chromatography (MEKC) method
 Melittin, 190
 Metformin, 125
 for diabetes, 127–128
 Metformin hydrochloride, 58–59, 63
 Methylglyoxal (MGO), 178
 Micellar electrokinetic chromatography (MEKC) method, 284
 Microencapsulation, 290–291
 Microtubule-associated protein 2 (MAP2), 163
 Microwave assisted cloud-point extraction (MACPE), 206
 Microwave-assisted extraction (MAE),
 flavonoids, 202–206
 Modern diagnosis vs. traditional diagnosis, 103
 Molecular electrostatic potential (MESP), 67
 Molecular imprinting technology (MIT), 211
 Molecularly imprinted solid phase (MISP)
 extraction, 283–284

Molegro Virtual Docker software, 258
 Moraprenyl monophosphate, chromatograms
 of, 41, 41f
 (–)-Mucocin, total synthesis of, 15, 16s
 Mukaiyama oxidative cyclization, 5f
 aerobic, 3–12
 bioactive molecules, synthesis of, 13–26
 double bond and alcohol substitution, 9–12
 mechanistic investigation of, 5–6, 7–8s
 second generation catalyst, 7, 8f
 synthetic variations of, 8–9, 9s
 Multi-target Quantitative Structure-Activity
 Relationship (mt-QSAR) study, 258
 Myristoylation, 62
 Myristoyl moiety, 60–61, 61f

N

Nanoformulated ART (NanoART), 264
 Nano-liquid chromatography (Nano-LC),
 337–338, 345–346
 Naringenin (NGN), 217–218
 Natural deep eutectic solvents (NADESs), 207
 Natural drugs, 92
 chemical drug developments, 100
 from Chinese medicine books, 97, 98–99t
 medicinal chemistry, 92–93
 pharmacology, 92–93
 Western version, 109f
 Natural products, 65–81, 157
 for Alzheimer's disease (AD), 159–170
 antioxidant activity evaluation, 358–364
 cultured plant extracts, 363–364
 fruits, 363
 herbs, 363
 lettuce, 362
 lipophilic compounds, 364
 mangosteen, 364
 paramagnetic impurities, detection of,
 366–367
 Piptadeniastrum africanum, 363
 silymarin, 361–362
 tea, 362
 in neurodegenerative diseases, 157–158
 Neoplasm metastasis, 107–108
 Nephroprotective activity, 289
 Nephrotoxicity, of chemotherapeutic drug
 cisplatin, 289
 Neural cell adhesion molecule (NCAM), 162
 Neurofibrillary tangles (NFTs), 158–159
 Neuronal nitric oxide synthase (nNOS), 166
 Nigranoic acid, 247–248
 Nitidine, 247–248

N-methyl-D-aspartate (NMDA) receptors, 158–159
 Nomilin, 251–252
 Non-insulin dependent diabetes mellitus (NIDDM), drug treatment for, 125
 Normal-transit constipation, 307–308
 Nuclear export signal (NES), 228–229
 Nuclear localizing signal (NLS), 228–229
 Nucleoside diphosphate sugar (NDPS), 49–50
 Nucleotide, 101–102

O

Oleanolic acid (OA), 79–81
 Opioid antagonists, 311
 Oral hypoglycemic drugs (OHD), 125
 Orbitrap-mass spectrometry, 340–341, 341*f*, 345
 Organic polysaccharides, 309
 Osmotic laxatives, 310
 Oxidation-reduction hydration reaction, 3–5, 4*f*
 Oxidative stress, 358
 hyperglycemia and, 123–124
 Oxygen (O₂), 3

P

PAC. *See Phellodendri Amurensis Cortex (PAC)*
Panax ginseng, for Alzheimer's disease (AD), 166–170
 Parkinson's disease (PD), 287
 PAs. *See Pyrrolizidine alkaloids (PAs)*
 Patentiflorin A, 247–248
 Pectenotoxin-4
 synthesis of, 22–23, 23*f*
 Pectenotoxin (PTX), 22–23
 Pencil graphite electrode (PGE), 217–218
 Pentenols, alkyl chain of, 11, 12*s*
 Peptides, 345–346
p-fluorophenol, 21–22
 Pharmacological treatments, of constipation
 bulking laxatives, 309
 colonic secretagogues, 310–311
 HT4 receptor agonists, 310
 Kampo/herbal medicine, 311
 opioid antagonists, 311
 osmotic laxatives, 310
 stool softeners, 310
 Pharmacology, 92–93
 Pharmacology, saffron, 274–275, 276–280*t*
 anti-Alzheimer's activity, 286
 anti-cancer/anti-tumor activities, 288–289

 anti-depressant activity, 287–288
 antidiabetic activity, 287
 antihypertensive activities, 285
 anti-inflammatory activity, 286
 anti-nociceptive activity, 286
 antioxidant activity, 286–287
 anti-Parkinson's activity, 287
 aphrodisiac activity, 285–286
 cardioprotective activities, 285
 nephroprotective activity, 289
 vasodilatory activities, 285
Phellodendri Amurensis Cortex (PAC), 346–347
 11-Phenoxyundecanoic acid, 37
 11-Phenoxyundecanol, 39
 11-Phenoxyundecanol (PhOU-OH),
 phosphorylation of, 37
 11-Phenoxyundecyl diphosphate
 2-acetamido-2-deoxy- α -D-glucose
 (PhOU-PP-GlcNAc), 44
 Phenoxyundecyl diphosphate α -D-galactose
 (PhOU-PP-Gal), 44
 11-Phenoxyundecyl diphosphate α -D-GlcNAc
 (PhOU-PP-GlcNAc), 46
 11-Phenoxyundecyl diphosphate α -D-glucose
 (PhOU-PP-Glc), 44
 11-Phenoxyundecyl phosphate (PhOU-P),
 synthesis of, 37
 Phenylalanine, 198
 Phenylglyoxylic ketyl radical, 361, 361*f*
 Pheophytin A, 247–248
 Phosphoglycosyltransferases (PGTs), 32, 47–50
 Phosphomonoester synthesis, 34, 34*s*
 Phosphopolyprenols
 biochemical and biomedical application, 47–50
 groups, 32, 33*f*
 synthesis of, 33–47
 Phosphoroimidazolidates, 43–44
 Phosphorus oxychloride (POCl₃),
 phosphorylation using, 36–37, 37*s*
 Phosphorylated compounds, 32
 Phosphorylation
 of AMP-activated protein kinase (AMPK), 60
 with *bis*-(benzyloxy)-(diisopropylamino)-
 phosphine (BBDIP), 39–40, 39*f*
 with *bis*-(2-cyanoethyl) -*N,N*-
 diisopropylphosphoramidite (BCDIP),
 38, 38*f*
 with *bis*-(9H-fluoren-9-ylmethyl) -
 diisopropylamidophosphite (BFDIP),
 38–39, 38–39*f*
 of 11-phenoxyundecanol (PhOU-OH), 37

- Phosphorylation (*Continued*)
 of polyprenols on large scale, 40–41, 41f
 with tetra-*n*-butylammonium dihydrogen phosphate (TBAP), 33–36
 with trivalent phosphorus derivatives, 37–40
 using POCl₃, 36–37, 37s
- Phosprenyl, 51
- Physical activity, 124–125
- Phytochemicals, 242–247f, 252–254
- Phytochemistry, saffron apocarotenoids
 analytical methods for, 284
 biosynthesis of, 282–283
 chemical composition and chemistry, 282
 extraction method, 283–284
- Phytomedicine, development, 256–257
- Phytotherapy, 254–255
- Picrocrocin, 251–252, 283–284
- Pictet–Spengler reaction, 18–19
- Pine honey, 177
- Pioglitazone hydrochloride (PGZ●HCl), 64
- Piperine, cocrystallization of, 67
- Piptadeniastrum africanum*, antioxidant capacity of, 363
- Plants
 with broad-spectrum activity against HIV, 252–254
 clinical application in management of HIV infection, 254–256
 with inhibitory activity against
 HIV entry, 239t
 HIV integrase, 235–236t, 248–249
 HIV protease, 237–238t, 249–250
 HIV reverse transcriptase, 229–248, 231–234t
 viral targets, 240–241t
 used for diabetes mellitus (DM), 129, 131–147t
- Plasminogen, 122
- Plum, 320
- Pollen, 182–184, 183f
- Polyamide adsorbents, 210–211
- Polyherbal formulation, 148
- Polyketides, 2–3
- Polymorphonuclear leukocytes (PMNs), 121
- Polyphenols, 101–102t, 342–345
 beneficial effect of, 69
- Polyprenols, 31–32, 32f, 35
 phosphorylation of, 40–41, 41f
- Polyprenyl diphosphates
 chromatograms of, 36f
 synthesis of, 33–42
 from activated prenol derivatives, 42, 42s
 synthesis of mixtures of, 35–36, 36s
- Polyprenyl diphosphates sugars
 cleavage of, 44–45, 45s
 synthesis of, 43–47
- Polyprenyl monophosphate
 chromatograms of, 36f, 41, 41f
 synthesis of mixtures of, 35–36, 36s
- Polyprenyl monophosphate sugars, synthesis of, 42–43, 43f
- Polyprenyl phosphates, 32
 pyrophosphate synthesis using, 46–47, 47s
 synthesis of, 33–42
 as therapeutical preparations, 50–51
- Polyprenyl phosphoroimidazolidates, 43–44, 43s, 45s
- Polysaccharide, 101–102t
- Prebiotic foods, 323–324
- Pregnancy constipation, 308–309
- Pressurized solvent extraction (PSE),
 flavonoids, 207–208
- Proanthocyanidin A2, 249
- Probiotic foods, 323
- Production enhancement, saffron
 agronomical improvement, 290
 bioactive products, encapsulation of, 290–291
 biotechnological methods, 292–293
 biotechnology application, 291–292
 breeding advancement, 291–292
Crocus, cytogenetic investigation of, 293
 genes associated, with flowering, 291
 genetic diversity assessment, 293–294
 quality control, 294–295
- Prokaryotic undecaprenol (Und-OH), 33
- Propolis, 179–182, 180f
 antibacterial activity, 181
 antiinflammatory properties, 182
 antitumoral effects, 181–182
 aromatic acids, 180
 chemical composition of, 179
 pharmaceutical formulations of, 181
 plant bud resin, 179
 raw, 179, 180f, 181
- Prostatin, 251–252
- Protein, 101–102t
- Protein Data Bank (PDB) database, 257
- Proton magnetic resonance, 123
- Protopanaxadiol (PD), 77, 77s
- Protopanaxatriol (PT), 77, 77s
- Prucalopride, 310
- Punigluconin, 258
- Pyrophosphate synthesis
 using acetylated glycosyl phosphates, 44–46, 45s

- using acetylated glycosyl phosphoroimidazolides, 46–47, 47s
- using polyphenyl phosphates, 46–47, 47s
- using unprotected glycosyl phosphates, 43–44, 43s
- Pyrrolizidine alkaloids (PAs), 346–347

Q

Quercetin, 199

R

- rac*-epichlorohydrin, 21–22
- Radical scavenging activity, of oil, 364
- Raw honey, 177
- Raw propolis, 179, 180f
- Regulator of viral protein expression (Rev), 228
- Repandusinic acid, 247–248
- Response surface methodology (RSM), 207
- Resveratrol (RSV), 65–71
 - AMPK activation by, 68–69
 - cocrystals, 66–67
 - in diabetes treatment, 70–71
 - dissolution properties, 66
 - molecular structure of, 65s
 - SIRT1 activation, 69–70, 70f
 - solubility, 65–66
 - tabletability, 66
 - therapeutic benefit, 65
- Reverse transcriptase (RT), 229
- Robustaflavone, 247–248
- Rosiglitazone (RSG), 64
- Rosmarinus officinalis*, 159
- Royalactins, 187
- Royal jelly (RJ)
 - apalbumin, 187
 - apisimin, 187
 - commercial, 186
 - compositions, 186, 188–189
 - fatty acids, 187–188, 188f
 - fresh, 186–188, 187t
 - immunomodulatory effects, 188
 - immunostimulatory effect, 186
 - lyophilized, 186, 187t
 - proteins, 187, 188t

S

- Saffron flowering, 291
- Safranal, 285–286
- Sample cleanup techniques, flavonoids, 210–211
- Sample preparation, flavonoids, 200–201

SCARs. *See* Sequence characterized amplified regions (SCARs)

- Schisandra chinensis*, 347
- Sebacic acid (SEA), 187–188, 188f
- Secondary metabolites, 127, 148, 159
- Second generation Mukaiyama catalyst, 7, 8f
- Sensory neuropathy, 120–121
- Sephadex, 210–211
- Sequence characterized amplified regions (SCARs), 294–295
- Serotonin, 310
- Shikonin, 251–252
- Silica adsorbents, 210–211
- Silica gel column chromatography technique, 39–40
- Silybin, 361–362, 362f
- Silybum marianum*, 361
- Silymarin, antioxidant capacity of, 361–362
- Single electron transfer (SET), 5–6
- Single-stage Orbitrap mass analyzer, 339–340
- SIRT1, 69, 72–73
- Size exclusion chromatography (SEC), 211
- Slow transit constipation, 308
- SmI₂-induced reductive cyclization, 15
- Solid-phase extraction (SPE), 211
- Sonogashira cross-coupling, 17
- Sorbicillactones A, 263
- Soulattrolide, 247–248
- Spectrophotometric analysis, flavonoids, 215–216
- “Spring and parachute effect”, 67
- Sterols, 101–102t
- Stigmasterol, 169–170, 170f
- Stille coupling, 20
- Stool softeners, 310
- Sulfonylureas (SUs), 58, 125
- Supercritical carbon dioxide (SC-CO₂), 208–209
- Supercritical fluid extraction (SFE), flavonoids, 208–209
- Superoxide dismutase (SOD), 167–168
- Synthetic variations, of Mukaiyama oxidative cyclization, 8–9, 9s

T

- Tabletability, defined, 66
- Tannin, 101–102t
- TDZs, 64
- Tea, antioxidant capacity of, 362
- Tegaserod, 310
- 10-hydroxydecanoic acid (10-HSA), 187–188, 188f

Terpenes/terpenoids, 101–102*t*, 347
 Tetrahydropyrans, synthesis of, 9, 10*s*
 Tetra-*n*-butylammonium cation (TBA⁺), 34
 Tetra-*n*-butylammonium dihydrogen phosphate (TBAP), phosphorylation with, 33–36
 Thiazolidinediones (TZDs), 58
 Thiazolidine-4-one derivatives, 256–257
 Thiobarbituric acid reactive substances (TBARS), 286–287
 Thrombosis, hyperglycemia and, 122
 Time-of-flight mass spectrometry (TOF-MS), 341, 341*f*
 Tissue culture system, 292–293
 TOF-MS. *See* Time-of-flight mass spectrometry (TOF-MS)
 Tolbutamide, 125
 Total flavonoids contents (TFCs), 209–210
 Total synthesis
 of amphidinolide F, 25–26, 25*s*
 of (–)-aplysiallene, 20–21, 22*s*
 of aromin, 18, 19*s*
 of (+)-asimilobin, 14–15, 15*s*
 of (–)-asimilobin, 14–15, 15*s*
 of (+)-bovidic acid, 19–20, 20*s*
 of bullatacin, 16–17, 17*s*
 of CMI-977 (LDP 977), 21–22, 22*s*
 of cyclocapitelline, 18–19, 19*s*
 of gigantetrocin A, 13–14, 14*s*
 of (–)-goniotrionin, 17, 18*s*
 of (–)-mucocin, 15, 16*s*
 of putative chagosensine, 20, 21*s*
 Traditional Chinese medicines, therapeutic routes for, 95, 95*f*
 Traditional diagnosis vs. modern diagnosis, 103
 “Traditional Medicine Strategy 2014–2023”, 227, 255–256
 Transcriptional transactivator (Tat), 228
 2,5-*trans* diastereoselectivity, 9–10
trans-1,4-dichloro-2-butene, 13–14
 Transfer latency (TL), 163–164
trans-10-hydroxy-2-decenoic acid (10-HDA), 187–188, 188*f*
 Trivalent phosphorus derivatives, phosphorylation with, 37–40, 38*s*
 Troglitazone, 64
 Tumor necrosis factor (TNFα), 123
 Tumors, 103
 Two-electrode voltage-clamp method, 164–165
 Type 1 diabetes mellitus (T1DM), 58, 118
 Type 2 diabetes mellitus (T2DM), 58–59, 118
 Tyrosine, 198

U

UHPLC. *See* Ultra-high-performance liquid chromatography (UHPLC)
 Ultra-high-performance liquid chromatography (UHPLC), 336
 Ultra-high-pressure extraction (UPE), 207–208
 Ultrasound-assisted extraction (UAE), flavonoids, 206–207
 Unani, 130–149
 Undecaprenol, 38
 Unique Manuka factor (UMF), 178
 Unprotected glycosyl phosphates, pyrophosphate synthesis using, 43–44, 43*s*
 Ursolic acid (UA), 79–81, 250
 Uvaol, 250

V

Vascular endothelium, 122
 Vasodilatory activities, 285
 Vegetable oil oxidative stability, evaluation of, 364–365
 Velutin, 247–248
 Vinyl iodine, 15
 Viremia, 226
 Volatile apocarotenoids, 284

W

Water-soluble ginseng oligosaccharides (WGOS), 167–168
Wedelia trilobata, 347
 Wedelolactone, 249
 Wheat bran, 322–323
 Wild saffron species, 281
 Winter cherry. *See* *Withania somnifera*
 Withaferin A, 161–162, 162*f*, 164–165
 Withanamides A (WA), 160–161, 160*f*
 Withanamides C (WC), 160–161, 160*f*
Withania somnifera, for Alzheimer’s disease (AD), 160–166
 Withanolide A, 162, 162*f*, 164–165
 Withanolide D, 162, 162*f*
 Withanone, 162, 162*f*, 166
 Wittig reaction, 13–15
 World Health Organization (WHO), 126, 197–198

Z

“Zero-crossing” technique, 216